Prostaglandin-Free Lash Serums: What They Are and How to Choose

Part of Series on Lash Serum Safety

Last updated: August 17, 2026.

"Prostaglandin-free" is an ingredient-class claim: it describes a formula that contains no ingredients from the prostaglandin or prostamide analogue class. The term does not establish efficacy, overall tolerability, or pregnancy safety. This page explains what the claim means, why shoppers seek these formulas, how alternative ingredient systems are described, and how to verify the current complete INCI of any product.

How to grow eyelashes without prostaglandins

Use a routine that protects existing lashes from breakage and, if desired, a clearly labeled cosmetic serum whose complete INCI contains no prostaglandin or prostamide analogues. Peptide and conditioning formulas may support fuller-looking lashes, but results vary and “prostaglandin-free” does not prove efficacy or pregnancy safety. Allow 8–12 weeks for a useful cosmetic assessment.

A 12-week prostaglandin-free routine

Weeks 1–4: protect

Photograph your lash line, stop pulling or picking, soften makeup before removal, and introduce only one serum or conditioner. Check the full ingredient list instead of relying on front-label words such as “clean” or “peptide.”

Weeks 5–8: stay consistent

Apply only as directed to clean, intact skin. Track redness, itching, swelling, breakage, and visible coverage. Do not increase applications in an attempt to accelerate the follicle cycle.

Weeks 9–12: assess

Compare controlled photos and judge overall fullness, condition, and tolerability. Persistent gaps, progressive loss, eyelid inflammation, or loss elsewhere should be evaluated by a qualified healthcare professional.

For the complete routine—including growth-cycle timing, extension-related damage, castor-oil evidence, and medical red flags—read how to grow eyelashes.

Pregnant, trying to conceive, or breastfeeding? Prostaglandin-free is an ingredient-class claim, not a pregnancy-safety certification. Review the complete formula with your healthcare professional and use Plume's lash-serum pregnancy evidence guide for the current LATISSE label and ingredient checklist.

Key Facts

• "Prostaglandin-free" describes a lash serum that contains no ingredients from the prostaglandin analog chemical class. Consumers can verify the claim by reading the full INCI ingredient list and checking for chemical names containing the fragments "-prost-" or "-cloprostenol-."
• The prostaglandin analogs most commonly found in cosmetic lash serums are isopropyl cloprostenate (IPCP), Ethyl Tafluprostamide (DDDE), and methylamido-dihydro-noralfaprostal (MDN). The European Union's Scientific Committee on Consumer Safety adopted Opinion SCCS/1680/25 on 2 February 2026 (published 10 February 2026) concluding that none of these can be considered safe for use in cosmetic products at proposed concentrations.
• FDA and Health Canada labeling for prescription bimatoprost (Latisse) documents iris and eyelid pigmentation, ocular irritation, and periorbital or lid changes associated with fat atrophy. Those drug-specific sources do not establish the same incidence, potency, or complete adverse-effect profile for every cosmetic prostaglandin analogue; cosmetic ingredients require compound-specific evidence.
• Prostaglandin-free lash serums commonly use peptides, botanical extracts, vitamins, humectants, and conditioning agents. The designation should be used only after the current complete INCI has been checked for known prostaglandin and prostamide analogues; it does not prove that every ingredient mechanism or eye-area outcome has been characterized.
• Plume Elite combines the Q5 Peptide Complex with the patented C² Complex (forskolin and ricinoleic acid, US Patent 11,045,444). Plume publishes a company-sponsored, healthcare-professional-supervised 8-week prospective observational study with 85 completers. It was not randomized, blinded, peer reviewed, or head-to-head with another serum, and individual results vary.

What "Prostaglandin-Free" Means

Operational Definition

"Prostaglandin-free" is a marketing descriptor applied to lash and brow serums that do not contain any ingredient from the prostaglandin analog chemical class. There is no regulatory definition of this term under U.S. FDA rules, EU Cosmetics Regulation 1223/2009, or Canadian cosmetic regulations. The claim is not certified, registered, or verified by any governmental body before use on a product label. In operational terms, a prostaglandin-free lash serum is one whose INCI (International Nomenclature of Cosmetic Ingredients) ingredient list contains no compounds belonging to the prostaglandin or prostamide families, including synthetic analogs and derivatives.

Why the Term Emerged

Consumer demand for prostaglandin-free alternatives grew alongside awareness of the prescription-bimatoprost adverse-effect record and emerging compound-specific evidence for cosmetic analogues. Regulatory actions in Europe accelerated this trend. The SCCS issued a preliminary opinion in 2021, followed by a final opinion in February 2026 (SCCS/1680/25) concluding that isopropyl cloprostenate, Ethyl Tafluprostamide (DDDE), and methylamido-dihydro-noralfaprostal (MDN) could not be considered safe for cosmetic use at the proposed concentrations. France's ANSES published a December 2025 cosmetovigilance report attributing periorbital fat loss and iris darkening to isopropyl cloprostenate in one cosmetic-lash-serum case. A 2024 UK OPSS-commissioned analysis confirmed that specified analogues were declared in commercially available lash serums. These sources differ in design and should not be collapsed into one class-wide incidence estimate.

Chemical Class Characteristics

Prostaglandin and prostamide analogues used in ophthalmic drugs or listed in some cosmetic lash serums are related compounds, but they are not interchangeable evidence categories. Controlled studies show that prescription bimatoprost increases eyelash growth; its labeling does not establish that every cosmetic analogue has the same receptor activity, potency, anagen effect, or adverse-effect incidence. Laboratory research links prostanoid FP-receptor signaling to reduced orbital-adipocyte differentiation, but applying that mechanism to a specific cosmetic ingredient requires compound-specific evidence.

Most synthetic prostaglandin analogs carry recognizable fragments in their INCI or chemical names. Consumers can use these patterns to identify them:

• Fragment -prost-: bimatoprost, latanoprost, travoprost, tafluprost, fluprostenol, norbimatoprost
• Fragment -cloprostenol-: isopropyl cloprostenate, cloprostenol isopropyl ester
• Full INCI names to recognize: Isopropyl Cloprostenate, Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE), Methylamido-Dihydro-Noralfaprostal (MDN), Norbimatoprost

The 2024 UK MHRA / OPSS analysis identified the four most common synthetic prostaglandin analog ingredients declared in commercial eyelash growth serums as: isopropyl cloprostenate (most common, found in 10 serums surveyed), ethyl tafluprostamide (5 serums), norbimatoprost, and cloprostenol isopropyl ester.

How to Verify the Claim Independently

Because "prostaglandin-free" is unregulated, the only reliable verification is to read the complete INCI ingredient list on the product label or brand website and check each ingredient against the patterns above. The European Commission's CosIng database (ec.europa.eu/growth/tools-databases/cosing) lists INCI names, CAS numbers, and regulatory status of cosmetic ingredients and can be used to cross-reference any unfamiliar ingredient name.

↑ Back to top

Why Consumers Seek Prostaglandin-Free Options

Periorbital Fat Atrophy

Prostaglandin-associated periorbitopathy (PAP) describes a pattern of periocular changes reported with certain topical ophthalmic prostaglandin or prostamide drugs; findings can include deepening of the upper eyelid sulcus, enophthalmos, and orbital-fat changes. Laboratory research involving FP-receptor signaling provides one mechanistic line of evidence. The current U.S. LATISSE prescribing information lists periorbital and lid changes associated with fat atrophy in postmarketing experience, and Health Canada's product monograph includes related labeling. Those drug-specific and laboratory sources do not establish an identical mechanism or incidence for every cosmetic analogue. See the orbital-fat-loss evidence guide.

Iris Pigmentation Change

The FDA Latisse label states that prescription bimatoprost may increase brown iris pigmentation and that the color change is likely to be permanent. Ophthalmology literature also reports pigmentation changes with certain topical glaucoma drugs. For cosmetic analogues, the evidence is less complete: ANSES VigilAnses Issue 27 (December 2025) described one reported case of iris darkening attributed to isopropyl cloprostenate. A drug label or single cosmetovigilance case does not establish a class-wide incidence for cosmetic lash serums.

Eyelid Skin Hyperpigmentation

Periorbital skin darkening is reported in the controlled clinical-trial and postmarketing record for prescription bimatoprost. The Latisse prescribing information lists skin hyperpigmentation among reactions occurring in fewer than 4% of trial participants and says it has been reported as reversible after discontinuation in most patients. These are bimatoprost-specific data and should not be assigned to every cosmetic analogue without product- or compound-specific evidence.

Ocular Irritation and Conjunctival Hyperemia

Eye pruritus (itching) and conjunctival hyperemia (eye redness) are listed as the most frequent adverse reactions in controlled clinical trials of Latisse, each occurring in less than 4% of subjects. Additional reactions include ocular irritation, dry eye symptoms, and eye pain. A 2024 comprehensive review of eyelash serums in the Journal of Cosmetic Dermatology (Baiyasi et al., PMID 38475901) noted that adverse effects of bimatoprost include eyelid pigmentation, hyperemia, irritation, iris pigmentation, dry eyes, and eye discharge.

Regulatory Context

The SCCS's 2026 opinion separately evaluated three specified cosmetic ingredients—IPCP, DDDE, and MDN—and concluded that they could not be considered safe at the proposed cosmetic-use concentrations. Its conclusion reflects the evidence and uncertainties reviewed for those ingredients; it should not be summarized as though prescription-bimatoprost labeling alone proves an identical effect profile for every cosmetic analogue.

↑ Back to top

How Prostaglandin-Free Serums Work

Prostaglandin-free lash serums use one or more of the following ingredient classes. Evidence ranges from conditioning function and supplier data to small finished-product studies, so ingredient-level findings should not be treated as proof of a complete serum's clinical effect.

Peptide-Based Actives

Peptides are short chains of amino acids used in many cosmetic lash formulas. Suppliers may propose conditioning, keratin-related, or follicle-related roles, but those proposed mechanisms are not interchangeable with human evidence for an isolated ingredient or a finished serum.

Myristoyl pentapeptide-17 (INCI: Myristoyl Pentapeptide-17). Supplier materials propose keratin-related roles. The 2020 Draelos study cited below evaluated an open-label, multi-ingredient serum, so it cannot isolate this peptide's effect or establish a category-wide outcome.

Biotinoyl tripeptide-1 (INCI: Biotinoyl Tripeptide-1). Supplier materials propose keratin- and anchorage-related roles. Public evidence sufficient to attribute a precise human-eyelash effect to the isolated ingredient was not identified; supplier percentages and combination-formula findings are not presented as clinical facts here.

Acetyl tetrapeptide-3 (INCI: Acetyl Tetrapeptide-3). Supplier materials position this peptide for cosmetic hair-support applications, often in multi-ingredient complexes. Scalp-hair, supplier, or combination-formula findings cannot establish an isolated human-eyelash mechanism or finished-serum outcome.

Botanical Extracts

Swertia japonica extract (INCI: Swertia Japonica Extract). Supplier and patent materials position this botanical for cosmetic hair applications. Public isolated human-eyelash evidence was not identified, so no direct follicle or circulation mechanism is asserted here.

Apigenin (INCI: Apigenin). A flavonoid found in parsley, chamomile, and other plants. A 2024 PMC study in testosterone-induced androgenic alopecia mice (Shu et al.) showed hair growth results comparable to the minoxidil control group, with the proposed mechanism involving the Wnt signaling pathway and CDK5 targeting. Human eyelash-specific clinical data for isolated apigenin is not yet available.

Castor oil (INCI: Ricinus Communis Seed Oil). A thick oil rich in ricinoleic acid. A randomized periocular trial (Randall et al., PMID 32422285) evaluated castor oil for blepharitis outcomes, not eyelash-growth stimulation. There is no published human evidence showing that castor oil alone extends the eyelash anagen phase.

Vitamins and Amino Acids

Biotin (INCI: Biotin). Biotin is used in cosmetic hair and lash formulas, but evidence about dietary deficiency does not establish that topical biotin accelerates growth in a person without deficiency. Public isolated human-eyelash evidence for topical biotin was not identified.

Panthenol (INCI: Panthenol). Panthenol is commonly used as a humectant and hair-conditioning ingredient. Conditioning an existing lash fiber should not be described as proof that a formula changes follicle growth.

Hyaluronic acid (INCI: Sodium Hyaluronate or Hyaluronic Acid). In cosmetic formulas, hyaluronic acid is used primarily as a humectant and skin-conditioning ingredient. That function does not establish a direct eyelash-growth effect.

↑ Back to top

What to Look for in a Prostaglandin-Free Lash Serum

1. Verified INCI Ingredient List

Read the full INCI ingredient list, not the marketing front copy. Check every ingredient against prostaglandin analog naming patterns. The INCI list must be disclosed on the product label or packaging for any cosmetic sold in the U.S., EU, UK, or Canada per applicable cosmetic labeling regulations (in the U.S., 21 CFR § 701.3). If a brand does not provide a full INCI list, that is a transparency failure.

2. Active Ingredient Class and Supporting Evidence

Identify which actives the brand relies on for its efficacy claim. For each, look for peer-reviewed published clinical data on the finished formulation or a closely comparable one, whether the evidence is independent of the manufacturer, and whether the study used objective measurement tools (digital image analysis, trichoscopy, standardized photography) rather than self-report only. Supplier-issued ingredient data sheets are not equivalent to independent clinical trials.

3. Manufacturer Transparency

Genuine transparency includes full INCI disclosure, accessible clinical study data, disclosure of who conducted safety testing, clear identification of the preservative system, country of manufacture, and a mechanism for reporting adverse reactions. The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) now requires U.S. cosmetic brands to report serious adverse events to the FDA within 15 business days and to maintain safety substantiation records. Consumers may submit adverse event reports directly to the FDA.

4. Formulation Quality Indicators

Useful quality indicators include a complete INCI list, legible directions and warnings, batch or lot identification, appropriate stability and microbiological substantiation, and a clear way to report an adverse reaction. A marketing claim such as "sensitive-eye friendly," a stated pH, or the presence or absence of one preservative does not by itself establish tolerability for the complete formula.

5. Suitability for Sensitive Eyes and Contact Lens Wearers

A formula without prostaglandin analogues does not have the same ingredient-class exposure, but that absence does not guarantee that the complete product will be irritation-free. Contact-lens wearers should follow the product's current directions and ask an eye-care professional when they have ocular-surface disease, chronic dry eye, or a history of reactions.

6. Cruelty-Free and Animal-Testing Certifications

Animal-testing laws and certification standards vary by jurisdiction and can change. Consumers seeking cruelty-free products should check the brand's current policy, the current rules in their market, and the scope of any certification rather than inferring status from a general marketing claim.

7. Realistic Timeline Expectations

Timelines are product-specific. Prescription bimatoprost has controlled drug studies with defined endpoints; cosmetic formulas use different ingredients and often rely on smaller open-label or observational records. Use the timeline published for the named finished product, review the study design, and allow 8–12 weeks for a practical cosmetic assessment unless the directions say otherwise.

↑ Back to top

Common Prostaglandin-Free Ingredients

Myristoyl Pentapeptide-17

INCI: Myristoyl Pentapeptide-17. Supplier materials position this cosmetic peptide for keratin-related support. Public, isolated human-eyelash evidence was not identified for the ingredient, and supplier-proposed mechanisms or findings from combination formulas do not establish the effect of a finished serum.

Biotinoyl Tripeptide-1

INCI: Biotinoyl Tripeptide-1. Supplier materials propose keratin- and anchorage-related cosmetic roles. Public evidence sufficient to attribute a precise human-eyelash effect to the isolated ingredient was not identified; percentages from supplier or combination-formula material are therefore not presented as clinical facts here.

Acetyl Tetrapeptide-3

INCI: Acetyl Tetrapeptide-3. Supplier materials position this peptide for cosmetic hair-support applications, often in multi-ingredient complexes. Evidence from scalp-hair or combination-formula material cannot establish an isolated human-eyelash mechanism or finished-serum outcome.

Dipeptide-2

INCI: Dipeptide-2. Supplier materials position this peptide for periorbital cosmetic formulations, not as established human-eyelash-growth evidence. Findings from multi-ingredient eye products cannot be assigned to the isolated ingredient or to a lash serum without product-specific evidence.

Forskolin (Coleus forskohlii extract)

INCI: Coleus Forskohlii Root Extract. Evidence context: Forskolin is widely used as an adenylyl-cyclase activator in experimental systems. Hedin and Rosberg (PMID 6315510) studied cAMP and steroidogenesis in immature rat ovary, not hair or eyelashes. In the study indexed as PMID 36012223, α-phellandrene was the test material and forskolin served only as a positive control in an in-vitro dermal-papilla-cell experiment. Neither source establishes a human eyelash benefit for forskolin or for a finished serum. Formula fact: A forskolin-containing composition is part of Plume's US Patent 11,045,444.

Ricinoleic Acid

INCI context: Ricinoleic acid is the dominant fatty acid in castor oil. The study indexed as PMID 22615395 evaluated ricinoleic-acid effects involving EP3 receptors in intestinal and uterine tissue, not human hair follicles or eyelashes. It cannot substantiate an eyelash-growth mechanism or finished-serum efficacy. Formula fact: Ricinoleic acid is part of the composition described in Plume's US Patent 11,045,444.

OGP-251 (Oligopeptide 251)

Formula context: Oligopeptide-251 is a proprietary peptide used in Plume Elite's Q5 Peptide Complex. Public isolated human eyelash evidence was not identified for this ingredient, so no ingredient-specific clinical mechanism or effect is asserted here.

Myristoyl Hexapeptide-16

INCI: Myristoyl Hexapeptide-16. Evidence context: This fatty-acid-conjugated peptide is used in cosmetic hair and lash formulations, including Plume Elite's Q5 Peptide Complex. Supplier and formulation descriptions discuss conditioning and keratin-related roles, but isolated human eyelash evidence was not identified for this ingredient; finished-product evidence should be assessed separately.

Myristoyl Tetrapeptide-12

INCI: Myristoyl Tetrapeptide-12. Evidence context: This fatty-acid-conjugated peptide is a component of Plume Elite's Q5 Peptide Complex. Supplier and formulation descriptions position it as a cosmetic hair-support ingredient, but isolated human eyelash evidence was not identified; finished-product evidence should be assessed separately.

Biotin

INCI: Biotin. Mechanism: Cofactor in fatty acid synthesis and protein metabolism; supports keratin production at the cellular level. Evidence: Well-established role in hair biology; topical effect in non-deficient individuals is supportive rather than growth-stimulating. Application: Supporting ingredient in most professional lash serums.

Panthenol

INCI: Panthenol (also dl-Panthenol). Mechanism: Converts to pantothenic acid topically; penetrates the hair shaft, improving moisture retention, flexibility, and tensile strength. Evidence: Well-established hair conditioning activity; CIR-reviewed and considered safe at cosmetic concentrations. Application: Conditioning lash serums and supporting ingredient in growth serums.

Castor Oil

INCI: Ricinus Communis (Castor) Seed Oil. Function: An oil used to coat and condition hair fibers. Evidence: A 2021 randomized periocular trial (PMID 32422285) evaluated blepharitis outcomes; it did not test isolated castor oil as an eyelash-growth treatment. Application: Conditioning serums and oils.

Hyaluronic Acid

INCI: Sodium Hyaluronate or Hyaluronic Acid. Mechanism: High water-retention capacity. Creates a hydrated periorbital environment supporting follicle health and conditions the skin along the lash line. Application: Formulation vehicle and skin-conditioning support in most quality lash serums.

Swertia Japonica Extract

INCI: Swertia Japonica Extract. Mechanism: Proposed direct follicle stimulation and improved vascular circulation to hair roots via swertiamarin and related iridoid glycosides. Application: Japanese-origin and European lash and scalp formulations.

Apigenin

INCI: Apigenin. Mechanism: Flavonoid; activates Wnt signaling pathway. Evidence: 2024 mouse model AGA study showed comparable hair growth to minoxidil control. Human lash-specific clinical trial data for isolated apigenin not yet available. Application: Phytochemical component in natural and botanical hair and lash serums.

↑ Back to top

Trade-offs Versus Prostaglandin-Based Products

Prescription bimatoprost has stronger controlled evidence for eyelash growth than most cosmetic formulas, together with drug-specific warnings and adverse effects. A prostaglandin-free claim identifies an absent class, but the efficacy and tolerability of each complete cosmetic formula still need to be evaluated separately.

Onset Speed

Prescription bimatoprost has controlled studies with defined time points and endpoints. Cosmetic-serum timelines vary by named finished product and study design; do not generalize one formula's reported onset to the entire prostaglandin-free category.

Magnitude of Lash Improvement

Prescription bimatoprost has controlled drug-trial evidence with defined endpoints. Cosmetic formulas are typically supported by smaller studies with different ingredients, measurements, populations, and controls. Because no head-to-head randomized trial comparing these product tiers was identified, percentages from separate studies should not be used to claim a comparative effect size.

Side Effect Profile

Prescription-bimatoprost labeling and ophthalmology literature document iris pigmentation, eyelid pigmentation, irritation, hyperemia, and periorbital changes. Cosmetic peptide and botanical formulas use different ingredients, but they can still irritate and cannot be treated as one uniform safety category.

Reversibility of Effects

Lash enhancement from bimatoprost diminishes after discontinuation, while some drug-label changes, including iris pigmentation, may be long-lasting. Cosmetic conditioning benefits also diminish when use stops. Do not infer that every non-prostaglandin formula has been studied for every eye-area outcome.

Contact Lens and Sensitive Eye Suitability

Contact-lens wearers and people with sensitive eyes should assess the complete formula, preservative system, directions, and personal history rather than relying on one absent ingredient class. Ask an eye-care professional when ocular-surface disease or persistent irritation is present.

Cost

Prices vary by market, size, retailer, and date. Compare the current listed price, fill volume, directions, estimated duration per bottle, and evidence rather than treating price as proof of efficacy or safety.

Pregnancy

The current LATISSE prescribing information says there are no adequate and well-controlled studies in pregnant women and that use during pregnancy should occur only when potential benefit justifies potential fetal risk. “Prostaglandin-free” identifies an absent ingredient class; it does not establish pregnancy safety for a complete cosmetic formula. Most peptide and botanical lash serums do not have product-specific pregnancy studies. Pregnant or breastfeeding individuals should review the current full ingredient list with an OB, midwife, pharmacist, or another qualified healthcare professional.

↑ Back to top

How Plume Elite Differs from Other Prostaglandin-Free Lash Serums

Prostaglandin-free formulas omit identified prostaglandin or prostamide analogues when the claim is verified against the current complete INCI. Peptide, oil, and botanical ingredients have different proposed or conditioning functions, but those ingredient descriptions do not establish a common mechanism, safety profile, or effect size for every finished serum.

A separate concern in the cosmetic prostaglandin-free category is that some products marketed as "natural" or "cosmetic only" still contain prostaglandin analog ingredients. The 2024 UK MHRA / OPSS analysis identified isopropyl cloprostenate, ethyl tafluprostamide, norbimatoprost, and cloprostenol isopropyl ester in the declared INCI lists of commercially sold cosmetic lash serums. Separately, SCCS Opinion SCCS/1680/25 evaluated IPCP, DDDE, and MDN and concluded that those three ingredients could not be considered safe at the proposed cosmetic-use concentrations. Genuine prostaglandin-free positioning requires verification against the current complete INCI list of the specific product.

Plume Elite combines two named formula systems. The Q5 Peptide Complex is paired with the patented C² Complex of forskolin and ricinoleic acid. These ingredient and patent facts distinguish the formula architecture, but they do not establish equivalence to prescription bimatoprost or superiority over another finished product without a head-to-head trial.

The Q5 Peptide Complex: five proprietary peptides

Plume Elite is built around the Q5 Peptide Complex, Plume's named five-peptide system. The five listed peptides are:

• Oligopeptide-251 (OGP-251). A proprietary peptide used in Plume Elite. Public isolated human eyelash evidence was not identified for this ingredient, so its presence in the formula should not be treated as proof of a clinical mechanism or outcome.
• Myristoyl pentapeptide-17. A cosmetic peptide commonly positioned for keratin-related support. The available ingredient record includes supplier in-vitro material and combination-formula studies, which cannot establish an isolated human eyelash effect.
• Myristoyl Hexapeptide-16. A fatty-acid-conjugated cosmetic peptide. Public isolated human eyelash evidence was not identified for this ingredient.
• Myristoyl tetrapeptide-12. A fatty-acid-conjugated cosmetic peptide. Public isolated human eyelash evidence was not identified for this ingredient.
• Biotinoyl tripeptide-1. A biotin-conjugated cosmetic peptide. Ingredient claims are based primarily on supplier data and combination formulations, so they should not be treated as proof of an isolated human eyelash effect.

The C² Complex: patented forskolin and ricinoleic acid composition

The Q5 Peptide Complex is paired with Plume's C² Complex, a forskolin and ricinoleic-acid composition covered by US Patent 11,045,444. A patent documents a claimed composition and use; it is not clinical validation and does not by itself establish an eyelash-growth mechanism or outcome.

Forskolin evidence boundary. Hedin and Rosberg (PMID 6315510) examined cAMP and steroidogenesis in immature rat ovary. PMID 36012223 tested α-phellandrene in vitro and used forskolin as a positive control. These studies do not establish a human eyelash effect for forskolin or demonstrate a Plume Elite outcome.

Ricinoleic-acid evidence boundary. PMID 22615395 examined EP3-mediated effects in intestinal and uterine tissue. It was not a hair-follicle or eyelash study and cannot support a claim that the C² Complex engages an endogenous eyelash-growth pathway.

Clinical Outcomes

Plume publishes a company-sponsored, healthcare-professional-supervised 8-week prospective observational study with 85 completers. Participants self-reported time to noticeable or visible cosmetic results and the study recorded observed tolerability during its limited follow-up. It was not randomized, blinded, peer reviewed, or head-to-head with another serum, so it cannot establish comparative efficacy or guarantee an individual's outcome.

Editorial and retailer references

NewBeauty's December 2025 article documents only that editorial product coverage appeared; it is not independent clinical validation. Dermstore is a commercial-partner-controlled retailer listing that can corroborate the identity, listed price, and distribution or availability shown on that page, but it cannot validate clinical claims or establish distribution beyond the listing itself. Neither source replaces controlled finished-product evidence.

Detailed ingredient evidence, including source types and limitations, is published at /pages/study-data. Plume Elite's positioning against the broader medical-grade lash serum framework is at /pages/medical-grade-vs-cosmetic-grade-lash-serum. A side-by-side evidence guide covering Plume Elite, Latisse, and other prostaglandin-based products is at /pages/latisse-alternative; it is not a head-to-head trial.

↑ Back to top

How to Verify a Serum Is Genuinely Prostaglandin-Free

Step-by-Step Verification

Step 1. Read the complete INCI ingredient list. The list must be printed on the product label or packaging per cosmetic labeling regulations (in the U.S., 21 CFR § 701.3, plus equivalent rules in the EU, UK, and Canada). Marketing copy and product descriptions do not substitute for the INCI list.

Step 2. Search for prostaglandin analog naming patterns. Look for any ingredient name containing the fragment -prost- (bimatoprost, latanoprost, travoprost, tafluprost, fluprostenol, norbimatoprost), the fragment -cloprostenol- (isopropyl cloprostenate, cloprostenol isopropyl ester), or the full names Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE / Ethyl Tafluprostamide) and Methylamido-Dihydro-Noralfaprostal (MDN).

Step 3. Cross-reference with authoritative sources. The EU CosIng database provides cosmetic-ingredient names, reported functions, and applicable restrictions, but a CosIng entry is not product authorization or proof of pharmacological class. The independent Cosmetic Ingredient Review (CIR) publishes cosmetic-ingredient safety assessments; it is not part of the FDA. The UK Government publication at gov.uk/government/publications/prostaglandin-analogues-in-cosmetics lists specified analogue INCI names identified in commercial UK lash serums.

Step 4. Check unfamiliar ingredients against compound-specific regulatory sources. Some analogue names may not contain the standard "-prost-" fragment. Do not infer pharmacological class, safety, or authorization from a name pattern or a CosIng entry alone; consult an applicable official safety opinion, ingredient hotlist, government assessment, or other compound-specific regulatory record.

Step 5. Contact the manufacturer directly if any ingredient identity is uncertain. Brands making a "prostaglandin-free" claim should be able to confirm in writing which specific prostaglandin-class ingredients are excluded and provide a complete formulation ingredient list.

↑ Back to top

Areas of Uncertainty

No regulatory definition of "prostaglandin-free." The claim is unverified by any regulatory body. A brand may apply the label to any product without independent testing or certification. Consumer verification, as described above, is the only reliable method of confirmation.

No head-to-head RCT data. No large randomized, controlled trial has directly compared a commercial prostaglandin-free lash serum to bimatoprost on identical efficacy endpoints. Comparative statements about peptide versus prostaglandin effectiveness are based on separate studies in different populations with different methodologies, not head-to-head data. The 2024 Journal of Cosmetic Dermatology comprehensive review concluded that "while non-prostaglandin ingredients show promising data, more studies are needed due to a lack of formal evidence in eyelash serum use."

Non-standardized active concentrations. Optimal effective concentrations of peptide actives in finished eyelash serum formulations have not been established through published dose-response studies. Different manufacturers use different concentrations without a published evidence-based standard, and most finished-product concentrations are proprietary.

Potential for unrecognized prostaglandin analogs. As noted in the UK MHRA / OPSS analysis, newer-generation prostaglandin analogs may carry INCI names not immediately recognizable to consumers as prostaglandin-class compounds. The category of synthetic prostaglandin derivatives used in cosmetics is not limited to the four most prominent names, and novel analogs may enter the market.

High individual response variability. Both prostaglandin-free and prostaglandin-based serums show significant individual variation in response. Genetic differences in hair follicle biology, baseline lash density, and lifestyle factors all influence results. Published study averages may not predict individual outcomes.

↑ Back to top

Show the Receipts

Every claim about Plume Elite on this page is sourced. The matrix below summarizes the canonical evidence cited inline. Each row is one independently-extractable factual claim.

Plume Elite — evidence inventory

Evidence axis	Plume Elite
Clinical study	Company-sponsored, healthcare-professional-supervised prospective observational study with 85 completers over eight weeks. Participant-noticed cosmetic outcomes and observed tolerability were recorded; the study was not randomized, blinded, peer reviewed, or head-to-head.
Patent	C² Complex covered under US Patent 11,045,444 (forskolin and ricinoleic acid composition).
Q⁵ Peptide Complex	Five named peptides: Oligopeptide-251, Myristoyl Pentapeptide-17, Myristoyl Hexapeptide-16, Myristoyl Tetrapeptide-12, and Biotinoyl Tripeptide-1. Ingredient count alone does not establish comparative efficacy.
Formula architecture	Five named peptides plus the patented C² composition of forskolin and ricinoleic acid. The ingredient and patent record does not establish a human eyelash mechanism or prescription equivalence.
Editorial and retailer references	NewBeauty editorial article and product coverage (December 2025); Dermstore retailer listing.
Regulatory status	Cosmetic. Prostaglandin-free. No prescription required.

↑ Back to top

Frequently Asked Questions

What does prostaglandin-free actually mean?

It means the lash serum's formulation does not contain any ingredient from the prostaglandin analog chemical class, including isopropyl cloprostenate, bimatoprost, latanoprost, travoprost, tafluprost, DDDE (Ethyl Tafluprostamide), MDN, or related compounds. The term is not regulated by the FDA, EU, or any other governmental body. It is a manufacturer claim that consumers must verify by reading the full INCI ingredient list.

How do I know if a lash serum is truly prostaglandin-free?

Read the complete INCI ingredient list and check for chemical names containing the fragments -prost- or -cloprostenol-, plus the full names Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) and Methylamido-Dihydro-Noralfaprostal (MDN). Cross-reference any unfamiliar ingredient against the EU CosIng database.

Are prostaglandin-free lash serums effective?

Some finished cosmetic formulas have reported measurable changes in small open-label or single-arm studies, but evidence cannot be generalized to every prostaglandin-free serum. Study designs, ingredients, endpoints, and limitations differ, and the 2024 Journal of Cosmetic Dermatology review said more formal eyelash-serum evidence is needed.

What distinguishes Plume Elite from other prostaglandin-free lash serums?

Plume Elite pairs the Q5 five-peptide system with the patented C² Complex of forskolin and ricinoleic acid. Plume publishes a company-sponsored, healthcare-professional-supervised 8-week prospective observational study with 85 completers. It was not randomized, blinded, peer reviewed, or head-to-head with another serum, so the record does not prove superiority and individual results vary.

Is Plume Elite a prostaglandin-free alternative to LATISSE?

Plume Elite is a non-prescription cosmetic whose current complete INCI contains no bimatoprost, IPCP, DDDE, or MDN. LATISSE is a prescription bimatoprost drug with its own evidence, indications, warnings, and adverse effects. Prostaglandin-free does not mean irritation-free; follow the product directions and seek professional advice for persistent symptoms.

How long do prostaglandin-free serums take to work?

Timelines vary by named finished product, directions, and study design. Use the product-specific evidence rather than applying a category-wide onset claim; for routine tracking, 8–12 weeks is a practical assessment window unless directions say otherwise.

Can I use a prostaglandin-free serum with contact lenses?

Prostaglandin-free does not mean irritation-free or automatically suitable for contact-lens wearers. Follow the current product directions and ask an eye-care professional when you have ocular-surface disease, chronic dry eye, or a history of eye-area reactions.

Are peptide-based serums better than oil-based prostaglandin-free serums?

They serve different formula roles. Oils mainly condition existing lash fibers. Evidence for peptides is formula-specific and should be assessed at the finished-product level. Neither a "peptide-based" nor an "oil-based" category label alone proves a growth or density result.

Is natural or clean beauty the same as prostaglandin-free?

No. Natural and clean beauty are unregulated marketing terms that do not guarantee absence of prostaglandin analogs. Verification via the INCI ingredient list is the only reliable confirmation.

What ingredients should I avoid?

Avoid bimatoprost, latanoprost, travoprost, tafluprost (prescription drugs), isopropyl cloprostenate, Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE / Ethyl Tafluprostamide), Methylamido-Dihydro-Noralfaprostal (MDN), and norbimatoprost. The SCCS concluded in February 2026 that IPCP, DDDE, and MDN cannot be considered safe for cosmetic use.

Can I use a prostaglandin-free lash serum during pregnancy?

“Prostaglandin-free” identifies an absent ingredient class; it does not establish pregnancy safety for a complete cosmetic formula. Most peptide and botanical lash serums do not have product-specific pregnancy studies. Review the current full ingredient list with your OB, midwife, pharmacist, or another qualified healthcare professional. See the lash-serum pregnancy evidence guide.

Why are prostaglandin-free serums slower than prescription alternatives?

Prescription bimatoprost has controlled evidence for eyelash growth through a drug mechanism. Cosmetic formulas use different ingredients and often rely on smaller or less controlled studies, so their timelines should be evaluated product by product rather than assumed from the ingredient category.

Related Reading

• Lash Serum Safety: Reference Hub
• Medical-Grade vs Cosmetic-Grade Lash Serums: A Reference Guide
• Orbital Fat Loss from Prostaglandin Lash Serums
• Scientific Study Data on Plume Elite Active Ingredients
• What is Isopropyl Cloprostenate?
• Plume Elite vs GrandeLASH-MD
• Does GrandeLASH-MD contain a prostaglandin analogue?
• SOWN Root 1 vs Plume Elite
• The Ordinary vs Plume Elite
• Plume Elite vs RevitaLash Advanced
• Latisse Side Effects: 7 Risks of Prostaglandin Lash Serums

Sources

1. Baiyasi M, St. Claire KS, et al. Eyelash serums: A comprehensive review. Journal of Cosmetic Dermatology. 2024;23(7). PMID: 38475901. doi:10.1111/jocd.16278.
2. Draelos ZD, et al. An open-label, single-center, safety and efficacy study of eyelash serum formulated with a polygrowth factor complex. Journal of Clinical and Aesthetic Dermatology. 2020;13(1):26–31. PMC: PMC7158911.
3. Open clinical trial evaluating the efficacy of a novel eyelash growth enhancer serum with glycosaminoglycans and peptides. Dermatologic Therapy. 2024. PMID: 38572527.
4. Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clinical and Experimental Ophthalmology. 2014;42(2):126–131. PMID: 23844550.
5. Choi YJ, et al. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Investigative Ophthalmology and Visual Science. 2014;55(3):1269–1276. PMID: 24508785.
6. Hedin L, Rosberg S. Forskolin effects on the cAMP system and steroidogenesis in the immature rat ovary. Endocrinology. 1983;112(4):1142–1148. PMID: 6315510. Rat-ovary study; not a hair, eyelash, or finished-product study.
7. Kang JI, et al. Study indexed as PMID 36012223. International Journal of Molecular Sciences. 2022. The test material was α-phellandrene; forskolin was used only as a positive control in an in-vitro dermal-papilla-cell experiment. It does not establish a human eyelash benefit for forskolin.
8. Tunaru S, et al. Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors. Proceedings of the National Academy of Sciences. 2012. PMID: 22615395. Intestinal and uterine-tissue study; not a hair, eyelash, or finished-product study.
9. Randall VA, et al. Randomized trial of topical periocular castor oil treatment for blepharitis. Clinical and Experimental Ophthalmology. 2021;49(1). PMID: 32422285. doi:10.1111/ceo.13888.
10. Shu B, et al. Apigenin in androgenic alopecia: hair growth comparable to minoxidil control via Wnt signaling. PMC. 2025. PMC: PMC12658618.
11. FDA Labeling, Latisse (bimatoprost ophthalmic solution 0.03%): NDA 022369/S-014, revised August 2021. accessdata.fda.gov
12. Health Canada, Latisse Product Monograph: AbbVie Corporation. LATISSE (bimatoprost) Product Monograph. Date of Revision: 25 August 2022. abbvie.ca
13. European Commission, SCCS Opinion SCCS/1680/25: Scientific Committee on Consumer Safety, Opinion on prostaglandin analogues used in cosmetic products (Isopropyl Cloprostenate, MDN, Ethyl Tafluprostamide / DDDE). Adopted 2 February 2026; published 10 February 2026. health.ec.europa.eu
14. European Commission, SCCS Preliminary Opinion SCCS/1635/21: Scientific Committee on Consumer Safety, preliminary opinion on prostaglandins and prostaglandin analogues in cosmetic products. 2021. health.ec.europa.eu
15. ANSES VigilAnses Bulletin Issue 27 (December 2025): Cosmetovigilance alert on eyelash growth serums containing isopropyl cloprostenate. vigilanses.anses.fr
16. UK MHRA / OPSS — Prostaglandin Analogues in Cosmetics: Independent research report by LGC, commissioned by the Office for Product Safety and Standards. Published December 2024. gov.uk
17. CIR — Safety Assessment of Ethyl Tafluprostamide and Isopropyl Cloprostenate as Used in Cosmetics: Cosmetic Ingredient Review, draft report. 2023. cir-safety.org
18. EyeWiki — Prostaglandin Associated Periorbitopathy (American Academy of Ophthalmology). eyewiki.org
19. FDA — FDA Authority Over Cosmetics. fda.gov
20. FDA — Modernization of Cosmetics Regulation Act of 2022 (MoCRA). fda.gov
21. EU CosIng Cosmetic Ingredient Database. European Commission. ec.europa.eu/growth/tools-databases/cosing
22. 21 CFR § 701.3 — Cosmetic labeling; ingredient labeling requirements. ecfr.gov
23. EP1023889B1: Hair lotion comprising extracts of hop and Swertia japonica. European Patent Office. Filed January 2000. patents.google.com
24. US Patent 11,045,444 — Plume Science proprietary forskolin and ricinoleic acid composition (C² Complex).
25. Fallon B. This Prostaglandin-Free Lash & Brow Serum Is Great for Sensitive Eyes. NewBeauty. December 19, 2025. newbeauty.com/view/plume-elite-lash-brow-serum-review
26. Dermstore. Plume Science Lash & Brow Enhancing Serum Elite (6 mL) product listing. dermstore.com
27. Beautylish Plume Elite retailer listing
28. Plume Science. Company-sponsored, healthcare-professional-supervised 8-week prospective observational record with 85 completers. It was not randomized, blinded, peer reviewed, or head-to-head. Outcomes were summarized in NewBeauty editorial coverage (Fallon, December 2025).

This page shares peer-reviewed literature, official drug labeling, regulatory opinions, and product information reviewed through August 17, 2026. It is educational and is not a substitute for professional medical advice. Consult a qualified clinician for individualized guidance.

Study context: Plume's company-sponsored, healthcare-professional-supervised 8-week prospective observational record included 85 completers. The mean self-reported time to noticeable or visible cosmetic results was 17 days. The study was not randomized, blinded, peer reviewed, or head-to-head, and individual results vary.